US FDA Tiptoes Further Into Off-Label Use Discussions With CURE ID App
Executive Summary
App allows clinicians to discuss off-label treatments, but information is intended to be hypothesis-generating, not for regulatory use.
You may also be interested in...
REMS Integration Into Electronic Health Records To Be Tested By US FDA In Software Pilot
The prototype pulls information from the electronic record to fill out enrollment and other forms, but stakeholders say it must work for most, if not all, REMS drugs in order to be widely used.
Coccidioidomycosis Outlook Highlights The Limits Of Regulatory Incentives
The US FDA heard a lot about the structural, medical and especially financial barriers facing coccidioidomycosis, or Valley fever, drug development soon after the agency refused to qualify the rare fungal infection for priority review voucher incentives.
CURE ID Expands Into COVID-19; Oncology And Rare Diseases Are Next
After slow start early in SARS-CoV-2 pandemic, CURE ID now has more than 150 case reports of drugs to treat the coronavirus.